These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32334191)

  • 21. Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    Tian Y; Liu Z; Liu J; Huang B; Kang D; Zhang H; De Clercq E; Daelemans D; Pannecouque C; Lee KH; Chen CH; Zhan P; Liu X
    Eur J Med Chem; 2018 May; 151():339-350. PubMed ID: 29635166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Tian XT; Xie L
    Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Gu SX; Lu HH; Liu GY; Ju XL; Zhu YY
    Eur J Med Chem; 2018 Oct; 158():371-392. PubMed ID: 30223123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.
    Sun Y; Kang D; Da F; Zhang T; Li P; Zhang B; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2021 Mar; 214():113204. PubMed ID: 33567378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy.
    Sang YL; Pannecouque C; De Clercq E; Wang S; Chen FE
    J Med Chem; 2023 Apr; 66(7):4755-4767. PubMed ID: 36996328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity.
    Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2021 Jun; 111():104905. PubMed ID: 33895602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
    Li X; Lu X; Chen W; Liu H; Zhan P; Pannecouque C; Balzarini J; De Clercq E; Liu X
    Bioorg Med Chem; 2014 Oct; 22(19):5290-7. PubMed ID: 25150090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Li Y; Ding S; Balzarini J; Pannecouque C; De Clercq E; Liu H; Liu X
    ChemMedChem; 2013 Jul; 8(7):1117-26. PubMed ID: 23650275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
    Fu Z; Zhang T; Zhou Z; Kang D; Sun L; Gao S; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
    Bioorg Med Chem; 2021 Jul; 42():116239. PubMed ID: 34090079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.
    Lei Y; Han S; Yang Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32111013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles.
    Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    ACS Infect Dis; 2020 May; 6(5):787-801. PubMed ID: 31599568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Gu SX; Yang SQ; He QQ; Ma XD; Chen FE; Dai HF; Clercq ED; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Dec; 19(23):7093-9. PubMed ID: 22037050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
    ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Kang D; Fang Z; Li Z; Huang B; Zhang H; Lu X; Xu H; Zhou Z; Ding X; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2016 Sep; 59(17):7991-8007. PubMed ID: 27541578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
    Lu HH; Xue P; Zhu YY; Ju XL; Zheng XJ; Zhang X; Xiao T; Pannecouque C; Li TT; Gu SX
    Bioorg Med Chem; 2017 Apr; 25(8):2491-2497. PubMed ID: 28314514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
    Liu Z; Tian Y; Liu J; Huang B; Kang D; De Clercq E; Daelemans D; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2017 Nov; 140():383-391. PubMed ID: 28987601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
    Huang B; Wang X; Liu X; Chen Z; Li W; Sun S; Liu H; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Bioorg Med Chem; 2017 Aug; 25(16):4397-4406. PubMed ID: 28659246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.